Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Oncology > 2026 Vol. 1 > No. 2 > 100019
Next Article Previous Article
COMMENTARY   Open Access     Cite

The value and limits of artificial intelligence in perioperative immunotherapy for gastric cancer

  • 1.

    Department of Science and Education, Shenyang Mental Health Center, Shenyang 110168, China

  • 2.

    Department of Laboratory Medicine, Institute of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China

  • 3.

    Department of Gastric Surgery, Cancer Hospital of Dalian University of Technology; Liaoning Cancer Hospital & Institute, Shenyang 110042, China

More Information
  • Corresponding author: zhengboren1@126.com
  • Received Date:  April 05, 2026
    Accepted Date:  July 07, 2026
    Published Online:  July 10, 2026
The Innovation Oncology  1(2),  https://doi.org/10.59717/j.xinn-oncol.2026.100019  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Lorenzen S., Götze T.O., Thuss-Patience P., et al. (2024). Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: Interim results from the randomized, multicenter, phase II/III DANTE/IKF-s633 trial. J. Clin. Oncol. 42:410−420. DOI:10.1200/JCO.23.00975

    View in Article CrossRef Google Scholar

    [2] Shitara K., Rha S.Y., Wyrwicz L., et al. (2025). Pembrolizumab plus chemotherapy versus chemotherapy as perioperative therapy in locally advanced gastric and gastroesophageal junction cancer: Final analysis of the randomized, phase III KEYNOTE-585 study. J. Clin. Oncol. 43:3152−3159. DOI:10.1200/JCO-25-00486

    View in Article CrossRef Google Scholar

    [3] Janjigian Y.Y., Al-Batran S.E., Wainberg Z.A., et al. (2025). Perioperative durvalumab in gastric and gastroesophageal junction cancer. N. Engl. J. Med. 393:217−230. DOI:10.1056/NEJMoa2503701

    View in Article CrossRef Google Scholar

    [4] Huang W., Wang X., Zhong R., et al. (2025). Multimodal radiopathomics signature for prediction of response to immunotherapy-based combination therapy in gastric cancer using interpretable machine learning. Cancer Lett. 631:217930. DOI:10.1016/j.canlet.2025.217930

    View in Article CrossRef Google Scholar

    [5] Collins G.S., Moons K.G.M., Dhiman P., et al. (2024). TRIPOD+AI statement: Updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ 385:e078378. DOI:10.1136/bmj-2023-078378

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Xin X., Li Y. and Zheng G. (2026). The value and limits of artificial intelligence in perioperative immunotherapy for gastric cancer. The Innovation Oncology 1:100019. https://doi.org/10.59717/j.xinn-oncol.2026.100019
    Xin X., Li Y. and Zheng G. (2026). The value and limits of artificial intelligence in perioperative immunotherapy for gastric cancer. The Innovation Oncology 1:100019. https://doi.org/10.59717/j.xinn-oncol.2026.100019

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(248) PDF downloads(87)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.